资讯

EurekAlert!7 个月
Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity (IMAGE)
Figure 1: Cancer therapeutics targeting the NKG2A:HLA-E axis. The NKG2A:HLA-E interaction can be inhibited by antibodies targeting either NKG2A (monalizumab, BMS-986315) or HLA-E (3H4, TFL-033).